S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
A $226B Copper Spending Jackpot (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
A $226B Copper Spending Jackpot (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
A $226B Copper Spending Jackpot (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
S&P 500   4,080.11
DOW   34,589.77
QQQ   293.36
The AP Interview: IMF head urges China to end mass lockdowns
5X Potential Growth By 2030? Is This Little-Known Market About To Explode? (Ad)
Santa Claus Rally? Here’s What Needs to Happen
25 Ways to Improve Your Financial Situation in 1 Hour
A $226B Copper Spending Jackpot (Ad)
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Dark Clouds Are Gathering For Cloud Stocks 
Without Graphite, There Would Be ZERO EV Batteries! (Ad)
An inflation gauge closely tracked by the Federal Reserve slowed to a still-high 6% in October
Will Easing Of Covid Rules Slash Risk For Chinese EV Maker NIO?
NASDAQ:RDHL

RedHill Biopharma - RDHL Stock Forecast, Price & News

$0.36
+0.01 (+2.86%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.33
$0.37
50-Day Range
$0.35
$0.70
52-Week Range
$0.25
$3.37
Volume
813,280 shs
Average Volume
1.43 million shs
Market Capitalization
$18.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

RedHill Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Healthy
3.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of RedHill Biopharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.65) to ($0.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.95 out of 5 stars

Medical Sector

1039th out of 1,047 stocks

Pharmaceutical Preparations Industry

507th out of 512 stocks

RDHL stock logo

About RedHill Biopharma (NASDAQ:RDHL) Stock

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Stock News Headlines

RDHL RedHill Biopharma Ltd.
Redhill Biopharma Ltd.
RedHill Biopharma Ltd. (RDHL)
See More Headlines
Receive RDHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RedHill Biopharma and its competitors with MarketBeat's FREE daily newsletter.

RDHL Company Calendar

Last Earnings
11/30/2021
Today
12/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDHL
Employees
201
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.00
High Stock Price Forecast
$0.00
Low Stock Price Forecast
$10,000,000.00
Forecasted Upside/Downside
+2,677.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
0 Analysts

Profitability

Net Income
$-97,740,000.00
Net Margins
-116.69%
Pretax Margin
-92.96%

Debt

Sales & Book Value

Annual Sales
$85.76 million
Book Value
$0.17 per share

Miscellaneous

Free Float
49,096,000
Market Cap
$18.96 million
Optionable
Optionable
Beta
2.07

Key Executives

  • Mr. Dror Ben-Asher (Age 56)
    Co-Founder, Chairman & CEO
    Comp: $884.67k
  • Mr. Micha Ben-Chorin (Age 53)
    Chief Financial Officer
    Comp: $548.14k
  • Mr. Gilead Raday MPhil (Age 47)
    MSc, Chief Operating Officer
    Comp: $539.74k
  • Mr. Adi Frish (Age 52)
    Chief Corp. & Bus. Devel. Officer
    Comp: $519.65k
  • Mr. Rick D. Scruggs (Age 62)
    Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director
    Comp: $736.35k
  • Dr. Mark L. Levitt M.D.
    Ph.D., Chief Scientific Officer
  • Ms. Alexandra Okmian
    Sr. Bus. Devel. & Investor Relations Mang.
  • Kristin Comer
    VP, Gen. Counsel & Chief Compliance Officer
  • Ms. Valerie Graceffa
    VP of Sales
  • Mr. Rob Jackson
    Sr. VP of Sales & Marketing













RDHL Stock - Frequently Asked Questions

Should I buy or sell RedHill Biopharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RedHill Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RDHL shares.
View RDHL analyst ratings
or view top-rated stocks.

What is RedHill Biopharma's stock price forecast for 2023?

1 brokers have issued 1-year target prices for RedHill Biopharma's shares. Their RDHL share price forecasts range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 2,677.8% from the stock's current price.
View analysts price targets for RDHL
or view top-rated stocks among Wall Street analysts.

How have RDHL shares performed in 2022?

RedHill Biopharma's stock was trading at $2.58 at the start of the year. Since then, RDHL stock has decreased by 86.0% and is now trading at $0.36.
View the best growth stocks for 2022 here
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.02. The biotechnology company earned $21.61 million during the quarter, compared to analyst estimates of $23.41 million. RedHill Biopharma had a negative net margin of 92.96% and a negative trailing twelve-month return on equity of 9,208.02%. During the same period in the prior year, the business earned ($0.50) EPS.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.12%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $0.36.

How much money does RedHill Biopharma make?

RedHill Biopharma (NASDAQ:RDHL) has a market capitalization of $18.97 million and generates $85.76 million in revenue each year. The biotechnology company earns $-97,740,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does RedHill Biopharma have?

The company employs 201 workers across the globe.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The official website for the company is www.redhillbio.com. The biotechnology company can be reached via phone at 972-3541-3131, via email at investors@redhillbio.com, or via fax at 972-3541-3144.

This page (NASDAQ:RDHL) was last updated on 12/1/2022 by MarketBeat.com Staff